Intravenous recombinant tissue plasminogen activator was first approved for the treatment of acute ischemic stroke in the United States in 1996. Thrombolytic therapy has been proven to be effective in acute ischemic stroke treatment and shown to improve long-term functional outcomes. Its use is associated with an increased risk of symptomatic intracerebral hemorrhage as well as orolingual angioedema. Our goal is to outline the management strategies for these postthrombolysis complications.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530424 | PMC |
| http://dx.doi.org/10.1177/1941874415587680 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Orolingual Angioedema in Stroke Without r-tPA Treatment: Evidence for Insular and Opercular Contribution.
Stroke
June 2024
Department of Neurology and Stroke Unit, Katholisches Klinikum Koblenz-Montabaur, Germany.
Ipsilateral orolingual angioedema following rhTNK-tPA administration for acute ischemic stroke.
Am J Emerg Med
March 2024
Department of Neurology, Taixing People's Hospital, Taixing, Jiangsu 225400, China. Electronic address:
Recombinant human tenecteplase tissue-type plasminogen activator (rhTNK-tPA), a genetically modified variant of conventional alteplase with longer half-life and higher fibrin specificity, has now emerged as a reasonable choice for thrombolytic treatment of acute ischemic stroke (AIS) in China. Orolingual angioedema is a rare but potentially life-threatening complication of intravenous thrombolysis. Currently, there is no documented evidence of orolingual angioedema occurring after thrombolysis with rhTNK-tPA.
View Article and Find Full Text PDFTenecteplase-associated orolingual angioedema: A case report and literature review.
Am J Health Syst Pharm
April 2024
Department of Pharmacy, Licking Memorial Hospital, Newark, OH, USA.
Purpose: Orolingual angioedema (OA) secondary to administration of thrombolytic therapy is a rare, but serious, known adverse effect. Despite the lack of robust evidence for their use, C1 esterase inhibitors are recommended by guidelines for the treatment of refractory thrombolytic-associated OA. This report highlights the use of a C1 esterase inhibitor in a patient with tenecteplase-associated OA unresolved by antihistamine and corticosteroid therapy.
View Article and Find Full Text PDFIcatibant averting mechanical ventilation in acute ischemic stroke patient with alteplase-induced orolingual angioedema.
Eur J Neurol
April 2024
Second Department of Neurology, School of Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Background And Purpose: Orolingual angioedema (OA) represents a rare but life-threatening complication among patients with acute ischemic stroke treated with intravenous thrombolysis with alteplase. Novel agents, including icatibant, are recommended in resistant patients with alteplase-induced OA who have failed to respond to first-line therapies including corticosteroids, antihistamines, and/or adrenaline.
Methods: We present a patient with alteplase-induced OA who showed substantial clinical improvement following the administration of icatibant.
Ipsilateral Orolingual Angioedema Following Alteplase Administration for the Treatment of Suspected Acute Ischemic Stroke.
Cureus
May 2023
Internal Medicine, Meharry Medical College, Nashville, USA.
Intravenous tissue plasminogen activator (tPA) remains the standard of treatment for patients presenting with acute ischemic stroke within the treatment window. In most patients, this often leads to an effective and life-prolonging intervention in the acute setting. This is, however, not without complications, which sometimes could be potentially fatal.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!